Amla on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

Summary

Amla has demonstrated promising effects in the treatment of obesity, dyslipidemia, hypertension, insulin secretion, among others. The above mentioned findings show that Amla has an excellent potential for the prevention and treatment of metabolic syndrome.

Timeline

Start

2019-04-01

Primary completion

2021-10-30

Completion

2022-03-30

Publications

• Background Athyros VG, Mikhailidis DP. High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice. J Diabetes Complications. 2016 Jan-Feb;30(1):9-11. doi: 10.1016/j.jdiacomp.2015.07.012. Epub 2015 Jul 17. No abstract available.
• Background Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am. 2014 Mar;43(1):1-23. doi: 10.1016/j.ecl.2013.09.009.
• Background Martinez-Abundis E, Mendez-Del Villar M, Perez-Rubio KG, Zuniga LY, Cortez-Navarrete M, Ramirez-Rodriguez A, Gonzalez-Ortiz M. Novel nutraceutic therapies for the treatment of metabolic syndrome. World J Diabetes. 2016 Apr 10;7(7):142-52. doi: 10.4239/wjd.v7.i7.142.
• Background Variya BC, Bakrania AK, Patel SS. Emblica officinalis (Amla): A review for its phytochemistry, ethnomedicinal uses and medicinal potentials with respect to molecular mechanisms. Pharmacol Res. 2016 Sep;111:180-200. doi: 10.1016/j.phrs.2016.06.013. Epub 2016 Jun 15.
• Background Akhtar MS, Ramzan A, Ali A, Ahmad M. Effect of Amla fruit (Emblica officinalis Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. Int J Food Sci Nutr. 2011 Sep;62(6):609-16. doi: 10.3109/09637486.2011.560565. Epub 2011 Apr 18.
• Background Cerezo C, Segura J, Praga M, Ruilope LM. Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension. Curr Hypertens Rep. 2013 Jun;15(3):196-203. doi: 10.1007/s11906-013-0337-4.
• Background Perez-Rubio KG, Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA, Espinel-Bermudez MC. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2013 Oct;11(5):366-9. doi: 10.1089/met.2012.0183. Epub 2013 Jun 28.
• Background O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015 Jan;16(1):1-12. doi: 10.1111/obr.12229. Epub 2014 Nov 18.
• Background Mendez-Del Villar M, Gonzalez-Ortiz M, Martinez-Abundis E, Perez-Rubio KG, Cortez-Navarrete M. Effect of Irvingia gabonensis on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion. J Med Food. 2018 Jun;21(6):568-574. doi: 10.1089/jmf.2017.0092. Epub 2018 Jan 16.
• Background Ruilope LM, Nunes Filho ACB, Nadruz W Jr, Rodriguez Rosales FF, Verdejo-Paris J. Obesity and hypertension in Latin America: Current perspectives. Hipertens Riesgo Vasc. 2018 Apr-Jun;35(2):70-76. doi: 10.1016/j.hipert.2017.12.004. Epub 2018 Feb 1.
• Background Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012 Feb 14;59(7):635-43. doi: 10.1016/j.jacc.2011.08.080.
• Background Harano Y, Suzuki M, Koyama Y, Kanda M, Yasuda S, Suzuki K, Takamizawa I. Multifactorial insulin resistance and clinical impact in hypertension and cardiovascular diseases. J Diabetes Complications. 2002 Jan-Feb;16(1):19-23. doi: 10.1016/s1056-8727(01)00192-1.
• Background Lim S, Eckel RH. Pharmacological treatment and therapeutic perspectives of metabolic syndrome. Rev Endocr Metab Disord. 2014 Dec;15(4):329-41. doi: 10.1007/s11154-014-9298-4.
• Background Park SE, Park CY, Sweeney G. Biomarkers of insulin sensitivity and insulin resistance: Past, present and future. Crit Rev Clin Lab Sci. 2015;52(4):180-90. doi: 10.3109/10408363.2015.1023429. Epub 2015 Jun 4.
• Background Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab. 2015 Jan-Feb;19(1):160-4. doi: 10.4103/2230-8210.146874.
• Background Adams-Huet B, Devaraj S, Siegel D, Jialal I. Increased adipose tissue insulin resistance in metabolic syndrome: relationship to circulating adipokines. Metab Syndr Relat Disord. 2014 Dec;12(10):503-7. doi: 10.1089/met.2014.0092. Epub 2014 Aug 27.
• Background Krishnaveni M, Mirunalini S. Therapeutic potential of Phyllanthus emblica (amla): the ayurvedic wonder. J Basic Clin Physiol Pharmacol. 2010;21(1):93-105. doi: 10.1515/jbcpp.2010.21.1.93.
• Background D'souza JJ, D'souza PP, Fazal F, Kumar A, Bhat HP, Baliga MS. Anti-diabetic effects of the Indian indigenous fruit Emblica officinalis Gaertn: active constituents and modes of action. Food Funct. 2014 Apr;5(4):635-44. doi: 10.1039/c3fo60366k.
• Background Patel SS, Goyal RK, Shah RS, Tirgar PR, Jadav PD. Experimental study on effect of hydroalcoholic extract of Emblica officinalis fruits on glucose homeostasis and metabolic parameters. Ayu. 2013 Oct;34(4):440-4. doi: 10.4103/0974-8520.127731.
• Background Usharani P, Fatima N, Muralidhar N. Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study. Diabetes Metab Syndr Obes. 2013 Jul 26;6:275-84. doi: 10.2147/DMSO.S46341. Print 2013.
• Background Yang B, Liu P. Composition and biological activities of hydrolyzable tannins of fruits of Phyllanthus emblica. J Agric Food Chem. 2014 Jan 22;62(3):529-41. doi: 10.1021/jf404703k. Epub 2014 Jan 9.
• Background Zhang LZ, Zhao WH, Guo YJ, Tu GZ, Lin S, Xin LG. [Studies on chemical constituents in fruits of Tibetan medicine Phyllanthus emblica]. Zhongguo Zhong Yao Za Zhi. 2003 Oct;28(10):940-3. Chinese.
• Background Vasudeva N, Yadav N, Sharma SK. Natural products: a safest approach for obesity. Chin J Integr Med. 2012 Jun;18(6):473-80. doi: 10.1007/s11655-012-1120-0. Epub 2012 Jul 22.
• Background Kim HY, Okubo T, Juneja LR, Yokozawa T. The protective role of amla (Emblica officinalis Gaertn.) against fructose-induced metabolic syndrome in a rat model. Br J Nutr. 2010 Feb;103(4):502-12. doi: 10.1017/S0007114509991978. Epub 2009 Nov 2.
• Background Faizal P, Suresh S, Satheesh Kumar R, Augusti KT. A study on the hypoglycemic and hypolipidemic effects of an ayurvedic drug Rajanyamalakadi in diabetic patients. Indian J Clin Biochem. 2009 Jan;24(1):82-7. doi: 10.1007/s12291-009-0014-1. Epub 2009 May 8.
• Background Nain P, Saini V, Sharma S, Nain J. Antidiabetic and antioxidant potential of Emblica officinalis Gaertn. leaves extract in streptozotocin-induced type-2 diabetes mellitus (T2DM) rats. J Ethnopharmacol. 2012 Jun 26;142(1):65-71. doi: 10.1016/j.jep.2012.04.014.
• Background Nazish I, Ansari SH. Emblica officinalis - Anti-obesity activity. J Complement Integr Med. 2017 Dec 5;15(2):/j/jcim.2018.15.issue-2/jcim-2016-0051/jcim-2016-0051.xml. doi: 10.1515/jcim-2016-0051.
• Background Chen TS, Liou SY, Chang YL. Supplementation of Emblica officinalis (Amla) extract reduces oxidative stress in uremic patients. Am J Chin Med. 2009;37(1):19-25. doi: 10.1142/S0192415X09006680.
• Background Yokozawa T, Kim HY, Kim HJ, Okubo T, Chu DC, Juneja LR. Amla (Emblica officinalis Gaertn.) prevents dyslipidaemia and oxidative stress in the ageing process. Br J Nutr. 2007 Jun;97(6):1187-95. doi: 10.1017/S0007114507691971.
• Background Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012;52:275-301. doi: 10.1146/annurev-pharmtox-011711-113247. Epub 2011 Sep 19.

Drugs

Indications